MARKET

NTLA

NTLA

Intellia Therape
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.00
+0.06
+0.12%
Opening 10:50 05/19 EDT
OPEN
46.82
PREV CLOSE
46.94
HIGH
48.89
LOW
45.61
VOLUME
240.86K
TURNOVER
6.40M
52 WEEK HIGH
202.73
52 WEEK LOW
38.85
MARKET CAP
3.56B
P/E (TTM)
-9.3283
1D
5D
1M
3M
1Y
5Y
10 Biggest Losers in Cathie Wood’s Latest Portfolio
In this article, we discuss the 10 biggest losers in Cathie Wood’s latest portfolio. If you want to skip our detailed analysis of Wood’s hedge fund performance, history and stock selection, go directly to 5 Biggest Losers in Cathie Wood’s Latest Portfolio....
Insider Monkey · 2d ago
Investors might be losing patience for Intellia Therapeutics' (NASDAQ:NTLA) increasing losses, as stock sheds 14% over the past week
The last three months have been tough on Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, who have seen the...
Simply Wall St. · 05/11 17:40
Pfizer's $11.6 bln Biohaven buy could spark more biotech deals
reuters.com · 05/11 17:12
Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse
On Wall Street, some things never change. High inflation or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that th...
TipRanks · 05/10 12:26
Intellia Therapeutics stocks falls for third straight session after Q1 earnings miss
Intellia Therapeutics (NASDAQ:NTLA) shares dropped 9% Monday morning as two brokerages lowered their price targets on the stock. Oppenheimer cut its target on Intellia (NTLA) to $130 from $160, while maintaining
Seekingalpha · 05/09 15:10
10 Biggest Price Target Changes For Monday
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.
Benzinga · 05/09 12:47
--JMP Securities Lowers Intellia Therapeutics Price Target to $110 From $165, Market Outperform Rating Kept
MT Newswires · 05/09 11:33
--Oppenheimer Adjusts Intellia Therapeutics' Price Target to $130 From $160, Maintains Outperform Rating
MT Newswires · 05/09 09:22
More
No Data
Learn about the latest financial forecast of NTLA. Analyze the recent business situations of Intellia Therape through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

27.27%Strong Buy
63.64%Buy
9.09%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NTLA stock price target is 136.65 with a high estimate of 207.00 and a low estimate of 55.00.
High207.00
Average136.65
Low55.00
Current 47.49
EPS
Actual
Estimate
-1.57-1.18-0.78-0.39
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 440
Institutional Holdings: 69.51M
% Owned: 91.64%
Shares Outstanding: 75.85M
TypeInstitutionsShares
Increased
122
5.54M
New
62
314.68K
Decreased
117
2.85M
Sold Out
54
961.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
+0.24%
Key Executives
Non-Executive Chairman/Independent Director
Frank Verwiel
President/Chief Executive Officer/Director
John Leonard
Chief Financial Officer/Executive Vice President/Treasurer
Glenn Goddard
Executive Vice President/Chief Scientific Officer
Laura Sepp-Lorenzino
Executive Vice President/General Counsel/Secretary
James Basta
Executive Vice President
David Lebwohl
Independent Director
Muna Bhanji
Independent Director
Frederick Cohen
Independent Director
John Crowley
Independent Director
Caroline Dorsa
Independent Director
Jean-Francois Formela
Independent Director
Jesse Goodman
Independent Director
Georgia Keresty
No Data
No Data
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. The Company's CRISPR/Cas9 is a technology for genome editing, process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To fully realize the transformative potential of CRISPR/Cas9, the Company uses two primary approaches. The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which its delivery technology enables precise editing of disease-causing genes directly within specific target tissues. The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.